RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
15,03 USD
0,00%
(0,00) 1D
15,03 USD
0,00% (0,00)
todayPre-market
Closed: 30-сен., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RARE...
Mkt. cap
1,48 млд
Avg. vol.
5,68 млн
Volume
10,24 миң
52-wk high
39,89 USD
52-wk low
12,73 USD
EPS
-5,84 USD
Beta
0,32
Shares outstanding
98,59 млн
No. of employees
1 миң
Mkt. cap
1,48 млд
Avg. vol.
5,68 млн
Volume
10,24 миң
52-wk high
39,89 USD
52-wk low
12,73 USD
EPS
-5,84 USD
Beta
0,32
Shares outstanding
98,59 млн
No. of employees
1 миң
News stories
From web sources and news partners
Stock Titan
·
16 мүнөт мурун
One platform links cleaning, delivery and reception robots with facility staff
CNBC
·
30 мүнөт мурун
The Dow's rough month, Micron's revenue surge, Google launches Gemini 4 and more in Morning Squawk
Business Wire
·
31 мүнөт мурун
Faraday Future and FF EAI Robotics Ecosystem Inc. (Nasdaq: FFR) Jointly Address Key Investor Questions Regarding the Proposed Combination of FFAI's Robotics Business
Seeking Alpha
·
41 мүнөт мурун
New Month, Same Market Dynamics
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees1,37 миң
Founded2010
HeadquartersНовато, Калифорния, Америка Кошмо Штаттары
Sector-
Websiteultragenyx.com